Antonio Bertoletti is a world-renowned immunologist, currently serving as the Principle Investigator of the Emerging Infectious Diseases Programme at the Duke-NUS Medical School in Singapore. He has made significant contributions to the study of viral hepatitis, with a particular focus on the T cell response to hepatitis B and C viruses. Bertoletti's research has led to the development of new therapeutic strategies for hepatitis B and C, including the use of immune-based therapies in treating liver cancer patients. He is the co-founder of Lion TCR, a biotechnology company that focuses on developing TCR-T (T cell receptor-engineered T cell) therapy.